A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination with Elranatamab in Participants with Relapsed and/or Refractory Multiple Myeloma Read more
Phase 1, Open-Label Study of Autologous SIRPA-low Macrophages (SIRPant-M) a cellular therapeutic product Administered by Intratumoral Injection Alone or in Combination with Focal External-Beam Radiotherapy in Participants with Relapsed or Refractory Non-Hodgkin’s Lymphoma Read more
TP53-Altered Aggressive Large B-Cell Lymphoma Outcomes by Treatment Modality: A Multicenter Retrospective Review Read more
Multisite, retrospective chart review of practice patterns and outcomes in patients with early-stage classical HL at different institutions within the United States Read more
Characterization and treatment of daratumumab-associated infections in patients with multiple myeloma. Read more
Impact of novel salvage regimens in patients with relapsed/refractory primary mediastinal B-cell lymphoma prior to autologous stem cell transplant Read more
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL) Read more
Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody Read more
